07:27 AM EDT, 03/17/2026 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) reported a Q4 net loss Tuesday of $46.1 million, swinging from a net income of $13.4 million a year earlier.

Collaboration revenue for the quarter ended Dec. 31 was $2.8 million, down from $60.6 million a year earlier.

The company said it had cash, cash equivalents, restricted cash and marketable securities of $382.1 million as of Dec. 31, and together with proceeds from its 2026 offering, expects this to support planned operations and capital expenditures into 2029.

The company's shares fell 2.9% in premarket activity Tuesday.